Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Gouveia AG, Zalay OC, Chua KL, Moraes FY. Response evaluation after stereotactic ablative radiotherapy for localised non-small-cell lung cancer: an equipoise of available resource and accuracy. Br J Radiol. 2020 Feb 01; 93(1106):20190647.
-
Chen Z, Yin K, Zheng D, Gu J, Luo J, Wang S, Chen H. Marital status independently predicts non-small cell lung cancer survival: a propensity-adjusted SEER database analysis. J Cancer Res Clin Oncol. 2020 Jan; 146(1):67-74.
-
Ludmir EB, McCaw ZR, Grossberg AJ, Wei LJ, Fuller CD. Quantifying the benefit of non-small-cell lung cancer immunotherapy. Lancet. 2019 11 23; 394(10212):1904.
-
Cheng D, Ramos-Cejudo J, Tuck D, Elbers D, Brophy M, Do N, Fillmore N. External validation of a prognostic model for mortality among patients with non-small-cell lung cancer using the Veterans Precision Oncology Data Commons. Semin Oncol. 2019 Aug - Oct; 46(4-5):327-333.
-
Kachouie NN, Deebani W, Christiani DC. Identifying Similarities and Disparities Between DNA Copy Number Changes in Cancer and Matched Blood Samples. Cancer Invest. 2019; 37(10):535-545.
-
Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak N, Pierce J, Kim CS, Ferdous S, Burt DJ, Slane-Tan D, Gomes F, Moore D, Shah R, Al Bakir M, Hiley C, Veeriah S, Summers Y, Crosbie P, Ward S, Mesquita B, Dynowski M, Biswas D, Tugwood J, Blackhall F, Miller C, Hackshaw A, Brady G, Swanton C, Dive C. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019 10; 25(10):1534-1539.
-
Joshi K, Robert de Massy M, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Werner Sunderland M, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Swanton C, Quezada SA, Chain B. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat Med. 2019 10; 25(10):1549-1559.
-
Miller PG, Li G, Singal G. PD-L1 Status and Survival in Patients With Lung Cancer-Reply. JAMA. 2019 08 27; 322(8):783-784.
-
Craig M, Kaveh K, Woosley A, Brown AS, Goldman D, Eton E, Mehta RM, Dhawan A, Arai K, Rahman MM, Chen S, Nowak MA, Goldman A. Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer. PLoS Comput Biol. 2019 08; 15(8):e1007278.
-
Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019 08 09; 10(1):3604.